PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8846779-3	1995	Activation of a phosphatidylcholine-specific phospholipase C (PC-PLC) was also detected which appeared to be a requirement for subsequent acidic sphingomyelinase (aSMase) activation, since PC-PLC inhibitor D609 blocked Fas/APO-1-induced aSMase activation, but not Fas/APO-1-induced neutral sphingomyelinase (nSMase) activation.	tricyclodecane-9-yl-xanthogenate	206-210	sphingomyelin phosphodiesterase 1	Homo sapiens	138-161	
8846779-3	1995	Activation of a phosphatidylcholine-specific phospholipase C (PC-PLC) was also detected which appeared to be a requirement for subsequent acidic sphingomyelinase (aSMase) activation, since PC-PLC inhibitor D609 blocked Fas/APO-1-induced aSMase activation, but not Fas/APO-1-induced neutral sphingomyelinase (nSMase) activation.	tricyclodecane-9-yl-xanthogenate	206-210	sphingomyelin phosphodiesterase 1	Homo sapiens	163-169	
27701117-5	2017	The effects of aSMase inhibition in vivo with D609 on pulmonary arterial pressure and inflammation were assessed following intratracheal administration of LPS.	tricyclodecane-9-yl-xanthogenate	46-50	sphingomyelin phosphodiesterase 1	Homo sapiens	15-21	
27701117-8	2017	Finally, administration of the aSMase inhibitor D609 limited the development of endotoxin-induced PH and ventilation-perfusion mismatch.	tricyclodecane-9-yl-xanthogenate	48-52	sphingomyelin phosphodiesterase 1	Homo sapiens	31-37	
18664717-4	2008	Treatment of D609 (aSMase inhibitor) decreased the level of basal and UV-induced MMP-1 expression.	tricyclodecane-9-yl-xanthogenate	13-17	sphingomyelin phosphodiesterase 1	Homo sapiens	19-25